CymaBay starts extension trial for seladelpar in liver disease

CymaBay Therapeutics Inc. (NASDAQ:CBAY) began a Phase II/III long-term extension trial to evaluate seladelpar (MBX-8025)

Read the full 150 word article

User Sign In